EmboTrap II Revascularization Device receives CE Mark approval to treat acute ischaemic stroke.- Neuravi

Neuravi, a company dedicated to improving clinical outcomes for stroke patients, announced Conformit� Europ�enne (CE) Mark approval and launch of the company�s newly available enhancements to the EmboTrap stent retriever platform, the EmboTrap II Revascularization Device.

Adoption of endovascular stroke therapy procedures for the treatment of acute ischemic stroke continues to grow significantly following compelling data from multiple large-scale randomized trials last year. These trials confirmed the value of using stent retriever thrombectomy to rapidly clear occlusive clots from large cerebral vessels. The novel EmboTrap was fully commercialized in Europe in 2015.

Comment:The Neuravi EmboTrap Revascularization Device is the first thrombectomy system designed with new understanding of clot-device mechanics to address challenging occlusions. The device is designed to retrieve clot with minimal compression, rapidly deliver TICI 2b-TICI3 reperfusion, and retain the clot while protecting against embolization during the procedure with the goal of improving outcomes and advancing the treatment of acute ischemic stroke. The EmboTrap II device is designed to address a broader range of clot lengths, with sizes that are deliverable through an 0.021� microcatheter.